Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 78,862	$ 228,182
Marketable securities	232,866	155,067
Prepaid expenses and other current assets	5,117	10,354
Other receivable	7,393	6,044
Total current assets	324,238	399,647
Restricted cash, non-current	20,070	20,000
Property and equipment, net	3,135	1,882
Operating lease right-of-use assets	4,362	4,763
Other non-current assets	37	51
Total assets	351,842	426,343
Current liabilities:
Accounts payable	2,019	3,231
Accrued expenses	17,871	9,976
Current portion of operating lease liabilities	1,750	1,125
Other current liabilities	387	760
Total current liabilities	22,027	15,092
Operating lease liabilities	3,017	3,709
Other liabilities	200	206
Nonrefundable research deposit	20,000	20,000
Total liabilities	45,244	39,007
Commitments and contingencies (Note 8)
Shareholders’ equity (deficit):
Ordinary shares, $0.000017100448 par value. 2,923,900,005 shares authorized as of September 30, 2022; 108,353,831 shares issued and outstanding as of September 30, 2022; 2,923,900,005 shares authorized as of December 31, 2021; 107,275,458 shares issued and outstanding as of December 31, 2021	2	2
Additional paid-in capital	728,915	713,269
Accumulated other comprehensive (loss) income	(3,844)	526
Accumulated deficit	(452,249)	(360,235)
Total LianBio shareholders’ equity	272,824	353,562
Non-controlling interest	33,774	33,774
Total shareholders’ equity	306,598	387,336
Total liabilities and shareholders’ equity	$ 351,842	$ 426,343